Ethanolic Extract of the Seed of *Zizyphus jujuba* var. *spinosa* Ameliorates Cognitive Impairment Induced by Cholinergic Blockade in Mice

Hyung Eun Lee<sup>1,2</sup>, So Young Lee<sup>3</sup>, Ju Sun Kim<sup>3</sup>, Se Jin Park<sup>1,2</sup>, Jong Min Kim<sup>1,2</sup>, Young Woo Lee<sup>1,2</sup>, Jun Man Jung<sup>1,2</sup>, Dong Hyun Kim<sup>1,2</sup>, Bum Young Shin<sup>1,4</sup>, Dae Sik Jang<sup>1,2</sup>, Sam Sik Kang<sup>3</sup> and Jong Hoon Ryu<sup>1,2,*</sup>

<sup>1</sup>Department of Life and Nanopharmaceutical Science, <sup>2</sup>Kyung Hee East-West Pharmaceutical Research Institute, <sup>3</sup>Natural Products Research Institute and College of Pharmacy, Kyung Hee University, Seoul 130-701, <sup>4</sup>College of Pharmacy, Kyung Hee University, Seoul 130-701, Republic of Korea

Abstract

In the present study, we investigated the effect of ethanolic extract of the seed of *Zizyphus jujuba* var. *spinosa* (EEZS) on cholinergic blockade-induced memory impairment in mice. Male ICR mice were treated with EEZS. The behavioral tests were conducted using the passive avoidance, the Y-maze, and the Morris water maze tasks. EEZS (100 or 200 mg/kg, p.o.) significantly ameliorated the scopolamine-induced cognitive impairment in our present behavioral tasks without changes of locomotor activity. The ameliorating effect of EEZS on scopolamine-induced memory impairment was significantly reversed by a sub-effective dose of MK-801 (0.0125 mg/kg, s.c.). In addition, single administration of EEZS in normal naïve mouse enhanced latency time in the passive avoidance task. Western blot analysis was employed to confirm the mechanism of memory-ameliorating effect of EEZS. Administration of EEZS (200 mg/kg) increased the level of memory-related signaling molecules, including phosphorylation of extracellular signal-regulated kinase or cAMP response element-binding protein in the hippocampal region. Also, the time-dependent expression level of brain-derived neurotrophic factor by the administration of EEZS was markedly increased from 3 to 9 h. These results suggest that EEZS has memory-ameliorating effect on scopolamine-induced cognitive impairment, which is mediated by the enhancement of the cholinergic neurotransmitter system, in part, via NMDA receptor signaling, and that EEZS would be useful agent against cognitive dysfunction such as Alzheimer’s disease.

Key Words: *Zizyphus jujuba* var. *spinosa*, Scopolamine, Memory impairment

INTRODUCTION

Dementia is a series of symptoms that is represented by lack of cognitive capabilities or memory impairment, and mainly caused by Alzheimer’s disease (AD) or vascular dementia. Especially, the pathological hallmark of AD is the loss of cholinergic neurons in the basal forebrain that innervate the neocortex and hippocampus involved in learning and memory (Daulatzai, 2010; Schliebs and Arendt, 2011). Therefore, the most effective agent for dementia would be expected to have neuroprotective and enhancing effects on the cholinergic neurotransmitter system. Donepezil, developed by those hypotheses, is a prescribed drug for AD (Birks et al., 2000). However, there are several issues to be overcome such as nausea, diarrhea, anorexia, or vomiting (Shintani and Uchida, 1997; Farlow et al., 2011). We are working on the development for anti-annemic or anti-dementic agent using in vivo screening from herbal materials which are traditionally known to be active to the central nervous system (CNS).

The seed of *Zizyphus jujuba* var. *spinosa* (Rhamnoceae) has been used for traditional medicine in many Asian countries as a hypnotic agent. Most of the previous studies about the seed of *Z. jujuba* var. *spinosa* have been focused on its traditional use as sedative or hypnotic agent. Jujubosides, some of the main components in *Z. jujuba* var. *spinosa*, have been suggested to play roles in hypnotic effects, and serotonergic neurotransmitter systems may be involved in their hypnotic effects (Cao et al., 2010). Jujubogenin, which easily pen-
etrates into blood brain barrier, is one of active constituents in *Z. jujuba* var. *spinosa* against insomnia by the activation of the GABA<sub>B</sub> receptor (Chen *et al.*, 2008). In addition, methanolic extract of the seed of *Z. jujuba* var. *spinosa* protects NMDA-induced neuronal cell damage in cultured rat cerebellar granular cells in vitro (Park *et al.*, 2004). However, there is no report regarding with the cognitive function of the seed of *Z. jujuba* var. *spinosa*.

In the present study, we wanted to investigate whether the ethanolic extract of the seed of *Z. jujuba* var. *spinosa* (EEZS) has memory-ameliorating effect on scopolamine-induced cognitive impairment or memory enhancing effect in normal naive mice. We employed several behavioral tests including the passive avoidance task, the Y-maze task and the Morris water maze task. Moreover, Western blot analysis was also employed to confirm the effect of EEZS on the levels of memory-related biochemical parameters, including phosphorylation levels of extracellular signal-regulated kinase (ERK) or cAMP response element-binding protein (CREB), or the expression levels of brain-derived neurotrophic factor (BDNF).

### MATERIALS AND METHODS

#### Animals

Male ICR mice (25–30 g, 6 weeks old) were purchased from the Orient Co. Ltd., a branch of the Charles River Laboratories (GyeongGi-do, Korea). Mice were housed 5 per cage, provided with food and water *ad libitum* and kept under a 12 h light/dark cycle (light on 07:30–19:30 h) at a constant temperature (23 ± 1°C) and relative humidity (60 ± 10%). Animal treatment and maintenance were carried out in accordance with the Animal Care and Use Guidelines issued by Kyung Hee University. All experimental protocols were approved by the Institutional Animal Care and Use Committee of Kyung Hee University (approved number; KHP-2011-01-03).

#### Materials

Donepezil hydrochloride monohydrate, scopolamine hydrobromide, and dizocilpine (MK-801) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Rabbit polyclonal anti-phosphorylated ERK (pERK) antibody was purchased from Cell Signaling Technology (Cell Signaling, MA, USA). Rabbit polyclonal anti-CREB, rabbit polyclonal anti-BDNF and mouse polyclonal β-tubulin antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). An anti-phosphorylated CREB (pCREB) antibody was purchased from Chemicon (Temecula, CA, USA). All other materials were obtained from normal commercial sources and were of the highest grade available.

#### Preparation of herbal extracts and drug administration

The seed of *Z. jujuba* var. *spinosa* were cultivated at Jinan, Shandong province, China, harvested in October 2009, and authenticated by Dr. J. H. Lee, Dongguk University. A voucher specimen was deposited in the Herbarium of the Traditional Herb Research Center, Korea Food and Drug Administration (No.11E-1001). The seed of *Z. jujuba* var. *spinosa* (1,240 g) were crushed and extracted two times with 70% ethanol (3 L) under reflux (60°C) for 2 h. The extract was evaporated to dryness under reduced pressure to give the 70% ethanolic extract (94.5 g; yield, 7.6%). To ensure the quality, EEZS was standardized based on the amount of jujuboside A, A2, B or naringin using a Shisheido C18 CAPCELL PAK column (5 μm, 4.6×250 mm; Shisheido, Tokyo) (Fig.1). The mean level of jujuboside A in EEZS was 0.54%.

#### Passive avoidance task

Assessment of acquisition and retention trials of the passive avoidance task was carried out for 2 days. Testing was performed in a box consisting of two identical chambers (20×20×20 cm) with one illuminated with 50 W bulb and another non-illuminated chamber that were separated by a guillotine door (5×5 cm). The floor of the non-illuminated compartment was composed of 2 mm stainless steel rods spaced 1 cm apart as described previously (Park *et al.*, 2012). Mice were administered of EEZS (25, 50, 100 or 200 mg/kg, p.o.) or donepezil (5 mg/kg, p.o.) 1 h before an acquisition trial. The control group received 10% Tween 80 solution rather than EEZS. Mice were treated with scopolamine (1 mg/kg, i.p.) or 0.9% saline 30 min before the acquisition trial. Mice were initially placed in the illuminated compartment during the acquisition trial. The door between the two compartments was opened 10 s later. The door automatically closed when the mice entered the non-illuminated compartment, and a 3 s electrical foot shock (0.5 mA) was delivered through the stainless steel rods. Mice that did not enter non-illuminated compartment within 60 s after the opening of the door were excluded from retention trial. The retention trial was conducted 24 h after the acquisition trial by returning individual mice to the illuminated compartment. The time for the mouse to enter the dark compartment after the door opening was defined as latency in both trials. Latencies

![Fig. 1. Representative HPLC chromatogram of standard mixture (15 μg/ml) (A) and the 50% aq-methanolic extract of *Z. jujuba* var. *spinosa* (EEZS) (B). Jujuboside A was detected at around 47.09 min in this system. In the presented case, the concentration of jujuboside A in EEZS was 11.0 μg/ml. 1: jujuboside A, 2: jujuboside A2, 3: jujuboside B, I.S: naringin.](http://dx.doi.org/10.4062/biomolther.2013.043)
were recorded for up to 300 s. In a separate antagonism study, EEZS (100 or 200 mg/kg) was administered 1 h before the acquisition trial, and sub-effective dose of MK-801 (0.0125 mg/kg), an N-methyl-D-aspartate (NMDA) receptor antagonist, was treated after the administration of EEZS. Scopolamine (1 mg/kg) was administered 5 min after the treatment with MK-801. The acquisition trial was conducted at 25 min after the administration of scopolamine. The dose of MK-801 in the present study was used not to impair the passive avoidance task performance when administered alone (Kim et al., 2010; Park et al., 2010). In the memory enhancing study, EEZS (100 or 200 mg/kg) alone without scopolamine was administered 1 h before the acquisition trial. When the mouse entered the non-illuminated compartment, a 3 s electrical foot shock (0.25 mA) was delivered through the stainless steel rods to avoid ceiling effects. Other procedures were the same as described above.

Y-maze task

The Y-maze is a three-arm horizontal maze (40 cm-long and 3 cm-wide with 12 cm-high walls) in which the arms are symmetrically disposed at 120° angles from each other. The maze floor and walls were constructed of dark opaque polyvinyl plastic as described elsewhere (Kim et al., 2006). Mice were initially placed within one arm, and the sequence (i.e., ABC, CAB, or BCA but not BAB) one hour before the test, mice were administered EEZS (100 or 200 mg/kg, p.o.) or donepezil (5 mg/kg, p.o.). Control group animals received 10% Tween 80 solution rather than EEZS or donepezil. Scopolamine (1 mg/kg, i.p.) was introduced to induce memory impairment 30 min before the test. Maze arms were thoroughly cleaned with water spray between each test to remove residual odors and residues. The alternation score (%) for each mouse was defined as the ratio of the actual number of alternations to the possible number (defined as the total number of arm entries minus two) multiplied by 100 as shown by the following equation: % Alternation=\[\frac{\text{Number of alternations}}{\text{Total arm entries}}-2\] \times 100. The number of arm entries was used as an indicator of locomotor activity.

Morris water maze task

The Morris water maze is a circular pool (90 cm in diameter and 45 cm in height) with a featureless inner surface. The pool was filled to a depth of 30 cm with water containing 500 ml of black pigment (24 ± 1°C). The tank was placed in a dimly lit, soundproof test room with four visual cues. A black platform (6 cm in diameter and 29 cm high) was then placed in one of the pool quadrants. The first experimental day was dedicated to swimming training for 60 s in the absence of the platform. During the five subsequent days the mice were given two trials per session per day with the platform in place. When a mouse located the platform, it was permitted to remain on it for 10 s. If the mouse did not locate the platform within 60 s, it was placed on the platform for 10 s. The time interval between each trial per session was 30 min (Kim et al., 2006). During each trial session, the time taken and distance moved to find the hidden platform (latency time) was recorded using a video camera-based Ethovision System (Noldus, The Netherlands). One day after the last training trial session, mice were subjected to a probe trial session in which the platform was removed from the pool, allowing the mice to swim for 60 s to search for it. A record was kept of the swimming time in the pool quadrant where the platform had previously been placed. EEZS (100 or 200 mg/kg, p.o.) or donepezil (5 mg/kg, p.o.) was given 1 h before the first trial at each session at every consecutive day. Memory impairment in mice was induced by scopolamine administration (1 mg/kg, i.p.) at 30 min before the first trial in each session. Control group received 10% Tween 80 solution only.

Open field test

The open field test was conducted in clear black Plexiglas box (40×40×40 cm) equipped with a video-based Ethovision System (Noldus, The Netherlands) as described previously (Jung et al., 2006). Mice were administered EEZS (100 or 200 mg/kg, p.o.) or 10% Tween 80 solution 1 h before the test. Mice were initially placed in the center of the apparatus, and total distance moved was recorded for 1 h. The horizontal locomotor activity is expressed in terms of the total ambulatory distance.

Western blot analysis

Mice were decapitated immediately after the retention trial of the passive avoidance task or designated time points after the administration of EEZS in normal naive mice, and the brains were isolated for Western blotting. Isolated hippocampal tissues from both hemispheres were homogenized in ice-cold Tris-HCl buffer (20 mM, pH 7.4) containing 0.32 M sucrose, 1 mM EDTA, 1 mM EGTA, 1 mM PMFS, 1 mM sodium orthovanadate and one tablet of protease inhibitor (Roche, Seoul, Korea) per 50 ml of buffer. Samples of homogenates (15 μg of protein) were subjected to SDS-PAGE (8% gel for pERK, ERK, pCREB and CREB, 12% gel for BDNF and β-tubulin) under reducing conditions. Proteins were transferred to PVDF membranes in transfer buffer [25 mM Tris-HCl buffer (pH 7.4) containing 192 mM glycine and 20% v/v methanol] at 400 mA for 2 h at 4°C. Western blots were incubated for 2 h with a blocking solution (5% skim milk) at room temperature followed by incubation in a 1:5,000 dilution of anti-pERK, anti-ERK, pCREB and anti-CREB antibodies, or a 1:1,000 dilution of anti-BDNF and anti-β-tubulin antibodies for 24 h at 4°C. The blots were washed ten times with a solution of Tris-buffered saline/Tween 20 (TBST) and incubated in a 1:10,000 (for pERK, ERK, pCREB, CREB) or 1:3,000 (for BDNF and β-tubulin) dilution of horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. The blots were washed ten times with TBST, and developed using enhanced chemiluminescence (Amersham Life Science, Arlington Heights, IL). Immunoreactivity was analyzed using the Multi-gauge, bio-imaging program on an LAS-4000 mini (FujiFilm Lifescan USA, Stamford, CT, USA).

Statistics

Values are expressed as means ± S.E.M. The latencies in the passive avoidance task, the spontaneous alternation in the Y-maze task, and the swimming time in the probe trial of the Morris water maze test were analyzed by one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test for multiple comparisons. Western blot analysis was analyzed by one-way ANOVA followed by Tukey’s post-hoc analysis for multiple comparisons. The interactions between the agonist and the antagonist in the passive avoidance task
we adopted 100 or 200 mg/kg of EEZS for further study.

...time during the acquisition trial across all groups. Thereafter, changes in swimming speed within the target zone were analyzed by two-way ANOVA, and Tukey’s post-hoc test was used to perform pair-wise comparisons to determine antagonist or agonist effects. Training-trial latencies in the Morris water maze test were analyzed by two-way ANOVA followed by Tukey’s post-hoc analysis using the day as one variable and treatment as a second. Statistical significance was set at p<0.05.

RESULTS

EEZS ameliorates cognitive dysfunction induced by scopolamine on the passive avoidance task

The passive avoidance task was employed to investigate whether EEZS ameliorates memory impairment induced by scopolamine (1 mg/kg, i.p.) (Fig. 2). There were significant group effects in terms of step-through latency [F(6, 54)=27.96, p<0.05]. The reduction of step-through latency was observed in the scopolamine-injected group, but the administration of EEZS significantly reversed the latency reduction (100 or 200 mg/kg, p<0.05; Fig. 1), as observed in the donepezil-treated group. There were no significant differences in the latency time during the acquisition trial across all groups. Thereafter, we adopted 100 or 200 mg/kg of EEZS for further study.

EEZS ameliorates cognitive dysfunction induced by scopolamine on the Y-maze task

The Y-maze task was performed to examine the effect of EEZS on the spontaneous alternation behavior. A significant group effect was observed on the percent spontaneous alternation [F(4, 39)=7.561, p<0.05, Fig. 3A]. The percentage of spontaneous alternation in the scopolamine-treated group was significantly lower than that in the vehicle-treated control group (p<0.05), and the reduction of the spontaneous alternation was significantly ameliorated by EEZS (100 or 200 mg/kg, p.o.) or donepezil (5 mg/kg, p.o.) (p<0.05, Fig. 3A). However, the mean numbers of arm entries were similar across all experimental groups (Fig. 3B), which demonstrated that general locomotor activity was not affected by EEZS (Sarter et al., 1988).

EEZS ameliorates cognitive dysfunction induced by scopolamine on the Morris water maze task

The effect of EEZS (100 or 200 mg/kg, p.o.) on spatial learning and memory was evaluated using the Morris water maze task. As shown in Fig. 4A, the scopolamine-treated group exhibited longer escape latencies throughout the training days than the vehicle-treated control group. However, escape latencies of the EEZS (200 mg/kg, p.o.)- or donepezil (5 mg/kg, p.o.)-treated group were significantly shortened compared with those of the scopolamine-treated group during the training trial sessions 4 and 5 [trial session 4, F(4, 45)=5.439, p<0.05; trial session 5, F(4, 45)=5.520, p<0.05]. On the day following the final day of training sessions, the shortened swimming time within the target zone induced by scopolamine was significantly reversed by EEZS (100 or 200 mg/kg) or donepezil (p<0.05, Fig. 4B). However, there were no significant differences in swimming speed within the target zone across all groups (data not shown).

EEZS did not affect the locomotor activity in the open field test

To determine whether EEZS modifies stimulatory effect on the exploratory behavior, the open field test was performed and spontaneous locomotor activity was observed. EEZS-treated groups (100 or 200 mg/kg) had no significant changes in total ambulatory distances compared to the control group (p>0.05, Fig. 5).

The effect of EEZS is antagonized by MK-801 in the passive avoidance task

To determine whether the memory-ameliorating effect of EEZS is mediated via NMDA receptor signaling, sub-effective dose of MK-801 (0.0125 mg/kg) was co-treated with scopolamine to the EEZS-treated mice (100 or 200 mg/kg), and the...
The memory-enhancing effect of EEZS in the naive animal was evaluated using the passive avoidance task (Fig. 7). During the acquisition trial, there were no significant differences in the step-through latency between groups. The retention trial was performed 24 h after the acquisition trial. As a result, dose-dependent increase of the step-through latency was observed in the EEZS-treated group \( [F(2, 28)=3.946, p<0.05, \text{Fig. 7}] \). EEZS (200 mg/kg) significantly increased step-through latency compared with the vehicle-treated control \( (p<0.05) \).

**EEZS enhances cognitive performance in naive mice measured by the passive avoidance task**

The memory-enhancing effect of EEZS in the naive animal was evaluated using the passive avoidance task (Fig. 7). During the acquisition trial, there were no significant differences in the step-through latency between groups. The retention trial was performed 24 h after the acquisition trial. As a result, dose-dependent increase of the step-through latency was observed in the EEZS-treated group \( [F(2, 28)=3.946, p<0.05, \text{Fig. 7}] \). EEZS (200 mg/kg) significantly increased step-through latency compared with the vehicle-treated control \( (p<0.05) \).

**The effects of EEZS on the expression levels of pERK, pCREB or BDNF in the hippocampus**

The effect of EEZS on the levels of ERK or CREB phosphorylation in the hippocampus was determined using the Western blot analysis. Mice were sacrificed 1 h after the administration of EEZS (100 or 200 mg/kg). Significant group effects on the levels of memory-related signaling molecules in the hippocampus were observed in the EEZS-treated groups. The administration of EEZS (200 mg/kg) significantly increased the phosphorylation levels of ERK \( [F(2, 21)=3.975, p<0.05, \text{Fig. 8A}] \) or CREB \( [F(2, 19)=3.385, p<0.05, \text{Fig. 8A}] \) compared to the levels of vehicle-treated group. To investigate the changes of time-dependent BDNF levels in the hippocam-
DISCUSSION

In the present study, we investigated whether EEZS has memory-ameliorating effect on the scopolamine-induced amnesic mouse model. Scopolamine-induced amnesia model in rodents has been widely used to screen beneficial treatments for cognitive dysfunction (Polster, 1993; Potter et al., 2000). To examine the effect of EEZS, several behavioral tests were employed. First, the passive avoidance task was used to examine the behavioral outcome after the administration of EEZS. Scopolamine caused memory impairments, and EEZS significantly reversed these impairments. These results suggest that EEZS rescued the cognitive dysfunctions related to learning and memory in the cholinergic dysfunction state. Second, in the Y-maze task, the administration of EEZS improved spontaneous alternation impairment induced by scopolamine, suggesting that EEZS ameliorates short-term or working memory impairment in scopolamine-induced amnesic model (Sarter et al., 1988; Myhrer et al., 2003). We also observed the memory-ameliorating effect of EEZS in the Morris water maze task. The Morris water maze task is dependent on hippocampal function or spatial memory that is commonly assessed using the rodents (Morris, 1984; Barnes et al., 1996). EEZS significantly shortened the escape latencies during the training sessions, and also ameliorated scopolamine-induced reduction in swimming time within the quadrant where the target platform was existed during the probe trial session. According to these behavioral results, EEZS could be considered to have memory-ameliorating effect in the case of cholinergic dysfunction without affecting spontaneous locomotor activity.

It has been suggested that both cholinergic and glutamatergic neurotransmissions are related to the learning and memory processes. Furthermore, interactions between central cholinergic and glutamatergic neurotransmitter systems have been suggested to be a crucial role in memory formation (Gray et al., 1996; Shimohama et al., 1996; Timofeeva and Levin, 2011). Cooperations between cholinergic and glutamatergic neurotransmitter systems are also essential to induce BDNF-dependent long-lasting memory storage (Navakode and Korte, 2012) and necessary for the induction of long-term potentiation (Jerusalinsky et al., 1997). Moreover, increasing evidences indicate that NMDA receptor activity affects acetylcholine release in the basal ganglia (Ikarashi et al., 1998; Knauber et al., 1999; Palencia and Ragozzino, 2006). Thus, cholinergic neurotransmitter system would be associated with the NMDA receptor signaling. In the present study, the memory-ameliorating effects of EEZS on scopolamine-induced memory dysfunction were completely antagonized by a sub-effective dose of MK-801. The relation between NMDA receptor and Zizyphi semen extract in vivo was demonstrated by previous researchers (Park et al., 2004), and was also observed in the present study in vivo. Moreover, the administration of EEZS enhanced memory performances in a dose-dependent manner in naive mice. Because of its weak inhibitory effect on the acetylcholinesterase inhibition activity (data not shown), these results suggest that the ameliorating effects of EEZS on the cognitive dysfunction may be attributed to the activity of cholinergic neurotransmitter system which is also regulated by glutamatergic signaling. This possibility could be supported by the changes of memory-related signaling molecules.

The administration of EEZS significantly increased the levels of pERK or pCREB in the hippocampus. Furthermore, the time-dependent expression level of BDNF was significantly increased 3 h after, and lasted at least 9 h after the administration of EEZS. A growing number of evidences show that...
Recently, it has been reported that jujuboside A increases the cognitive behavioral tests. However, jujuboside A or B did not and obtained jujuboside A and B in large amount enough to al.

**REFERENCES**

**ACKNOWLEDGMENTS**

This research was supported by a grant (09112KFDA890) from Korean Food & Drug Administration in 2011.

**REFERENCES**

Barnes, C. A., Daniysz, W. and Parsons, C. G. (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. *Eur. J. Neurosci.* 8, 565-571.

Birk, J. S., Melzer, D. and Beppu, H. (2000) Donepezil for mild and moderate Alzheimer’s disease. *Cochrane Database Syst. Rev.*, CD001190.

Bourbouladze, R., Frenguelli, B., Blendy, J., Cioffi, D., Schultz, G. and Silva, A. J. (1994) Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. *Cell* 79, 59-68.

Cao, J. X., Zhang, Q. Y., Cui, S. Y., Cui, X. Y., Zhang, J., Zhang, Y. H., Bai, Y. J. and Zhao, Y. Y. (2010) Hypnotic effect of jujubosides from Semen Ziziphi Spinossae. *J. Ethnopharmacol.* 130, 163-166.

Chen, C. Y., Chen, Y. F. and Tsai, H. Y. (2008) What is the effective component in suanzaoen decoction for curing insomnia? Discovery by virtual screening and molecular dynamic simulation. *J. Biomed. Struct. Dyn.* 26, 57-64.

Dautlatzai, M. A. (2010) Early stages of pathogenesis in memory impairment during normal senescence and Alzheimer’s disease. *J. Alzheimers Dis.* 20, 355-367.

Davis, S., Vanhoutte, P., Pages, C., Caboche, J. and Laroche, S. (2000) The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. *J. Neurosci.* 20, 4563-4572.

English, J. D. and Sweet, D. J. (1996) Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation. *J. Biol. Chem.* 271, 24329-24332.

English, J. D. and Sweet, D. J. (1997) A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. *J. Biol. Chem.* 272, 19103-19106.

Farlow, M., Veloso, F., Moline, M., Yardley, J., Brand-Schieber, E., Bibbiani, F., Zou, H., Hsu, T. and Satlin, A. (2011) Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease. *BMC Neurol.* 11, 57.

Gray, R., Rajan, A. S., Radcliffe, K. A., Yakehiro, M. and Dani, J. A. (1996) Hippocampal synaptic transmission enhanced by low concentrations of nicotine. *Nature* 383, 713-716.

Guil-Guerrero, J. L., Diaz Delgado, A., Matallana Gonzalez, M. C. and Torija Isasa, M. E. (2004) Fatty acids and carotenoids in some berry (Ziziphus jujuba Mill) varieties. *Plant Foods Hum. Nutr.* 59, 23-27.

Ikarashi, Y., Yuzurhara, M., Takahashi, A., Ishimaru, H., Shiobara, T. and Maruyama, Y. (1996) Direct regulation of acetylcholine release by N-methyl-D-aspartic acid receptors in rat striatum. *Brain Res.* 795, 215-220.

Jerusalinsky, D., Komissiu, E. and Izquierdo, I. (1997) Cholinergic neurotransmission and synaptic plasticity concerning memory processing. *Neurochem. Res.* 22, 507-515.

Jung, J. W., Ahn, N. Y. Oh, H. R., Lee, B. K., Lee, K. J., Kim, S. Y., Cheong, J. H. and Ryu, J. H. (2006) Anxiolytic effects of the aqueous extract of Ucaria rhinophylly. *J. Ethnopharmacol.* 106, 193-197.

Kim, D. H., Hung, T. M., Bae, K. H., Jung, J. W., Lee, S., Yoon, B. H., Cheong, J. H., Ko, K. H. and Ryu, J. H. (2006) Gomisin A improves scopolamine-induced memory impairment in mice. *Eur. J. Pharmacol.* 542, 129-135.

Kim, D. H., Jung, H. A., Park, S. J., Kim, J. M., Lee, S., Choi, J. S., Cheong, J. H., Ko, K. H. and Ryu, J. H. (2010) The effects of daidzin and its aglycon, daidzein, on the scopolamine-induced memory impairment in male mice. *Arch. Pharm. Res.* 33, 1685-1690.

Knauber, J., Kischka, U., Roth, M., Schmidt, W. J., Hennerici, M. and Fassbender, K. (1999) Modulation of striatal acetylcholine concentrations by NMDA and the competitive NMDA receptor-antagonist AP-5: an in vivo microdialysis study. *J. Neural. Transm.* 106, 35-45.

Morrish, R. (1984) Developments of a water-maze procedure for studying spatial learning in the rat. *J. Neurosci. Methods* 11, 47-60.

Myhrer, T., Danscher, G. and Fonnum, F. (2003) Degenerative patterns following denervation of temporal structures in a rat model of menimonic dysfunction. *Brain Res.* 967, 293-300.

Navakkede, S. and Korte, M. (2012) Cooperation between cholinergic and glutamatergic receptors are essential to induce BDNF-dependent long-lasting memory storage. *Hippocampus* 22, 335-346.

Palancia, C. A. and Ragozzino, M. E. (2006) The effect of N-methyl-D-aspartate receptor blockade on acetylcholine efflux in the dorsomedial striatum during response reversal learning. *Neuroscience* 140, 671-678.

Park, J. H., Lee, H. J., Koh, S. B., Ban, J. Y. and Seong, Y. H. (2004) Protection of NMDA-induced neuronal cell damage by methanol extract of Ziziphi Spinosae Semen in cultured rat cerebellar granule cells. *J. Ethnopharmacol.* 95, 39-45.

Park, S. J., Kim, D. H., Jung, J. M., Kim, J. M., Cai, M., Liu, X., Hong, J. et al. *Effects of Ziziphus jujuba var. spinosa on Cognition*
G., Lee, C. H., Lee, K. R. and Ryu, J. H. (2012) The ameliorating effects of stigmasterol on scopolamine-induced memory impairments in mice. *Eur. J. Pharmacol.* **676**, 64-70.
Park, S. J., Kim, D. H., Lee, I. K., Jung, W. Y., Park, D. H., Kim, J. M., Lee, K. R., Lee, K. T., Shin, C. Y., Cheong, J. H., Ko, K. H. and Ryu, J. H. (2010) The ameliorating effect of the extract of the flower of Prunella vulgaris var. lilacina on drug-induced memory impairments in mice. *Food Chem. Toxicol.* **48**, 1671-1676.
Polster, M. R. (1993) Drug-induced amnesia: implications for cognitive neuropsychological investigations of memory. *Psychol. Bull.* **114**, 477-493.
Potter, D. D., Pickles, C. D., Roberts, R. C. and Rugg, M. D. (2000) Scopolamine impairs memory performance and reduces frontal but not parietal visual P3 amplitude. *Biol. Psychol.* **52**, 37-52.
Sarter, M., Bodewitz, G. and Stephens, D. N. (1988) Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. *Psychopharmacology (Berl)* **94**, 491-495.
Schliebs, R. and Arendt, T. (2011) The cholinergic system in aging and neuronal degeneration. *Behav. Brain Res.* **221**, 555-563.
Shimohama, S., Akaike, A. and Kimura, J. (1996) Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation. *Ann. N. Y. Acad. Sci.* **777**, 356-361.
Shintani, E. Y. and Uchida, K. M. (1997) Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. *Am. J. Health Syst. Pharm.* **54**, 2805-2810.
Tao, X., Finkbeiner, S., Arnold, D. B., Shaywitz, A. J. and Greenberg, M. E. (1998) Ca²⁺ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. *Neuron* **20**, 709-726.
Timofeeva, O. A. and Levin, E. D. (2001) Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia. *Neuroscience* **195**, 25-36.
Tully, T., Bourchouladze, R., Scott, R. and Tallman, J. (2003) Targeting the CREB pathway for memory enhancers. *Nat. Rev. Drug Discov.* **2**, 267-277.
Xu, Y., Lv, X. F., Cui, C. L., Ge, F. F., Li, Y. J. and Zhang, H. L. (2012) Essential role of NR2B-containing NMDA receptor-ERK pathway in nucleus accumbens shell in morphine-associated contextual memory. *Brain Res. Bull.* **89**, 22-30.
You, Z. L., Xia, Q., Liang, F. R., Tang, Y. J., Xu, C. L., Huang, J., Zhao, L., Zhang, W. Z. and He, J. J. (2010) Effects on the expression of GABA, receptor subunits by jujuboside A treatment in rat hippocampal neurons. *J. Ethnopharmacol.* **128**, 419-423.
Zhao, J., Li, S. P., Yang, F. Q., Li, P. and Wang, Y. T. (2006) Simultaneous determination of saponins and fatty acids in *Ziziphus jujuba* (Suanzaoren) by high performance liquid chromatography-evaporative light scattering detection and pressurized liquid extraction. *J. Chromatogr. A* **1108**, 188-194.
Zhou, X., Moon, C., Zheng, F., Luo, Y., Soellner, D., Nunez, J. L. and Wang, H. (2009) N-methyl-D-aspartate-stimulated ERK1/2 signaling and the transcriptional up-regulation of plasticity-related genes are developmentally regulated following in vitro neuronal maturation. *J. Neurosci. Res.* **87**, 2632-2644.
Zheng, F., Zhou, X., Moon, C. and Wang, H. (2012) Regulation of brain-derived neurotrophic factor expression in neurons. *Int. J. Physiol. Pathophysiol. Pharmacol.* **4**, 188-200.